Newsroom

News and Press Releases

Here you can read news and press releases from Paindrainer. We also available positions so keep your eyes open.

No items found.
12/2/2024

Paindrainer AB launches a pioneering Remote Therapeutic Monitoring (RTM) platform for innovative chronic pain management

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, a forerunner in digital medical device solutions for chronic pain, is pleased to introduce the Paindrainer Care Portal, which together with the Paindrainer PD1 mobile application offers a complete solution for health care professionals to remotely monitor their patients’ progress and improve their quality of life.

Read more
No items found.
1/16/2024

Paindrainer AB selected for the groundbreaking 10XHEALTH Scaleup Program with a focus to accelerate growth in Swedish Life Science companies

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, a pioneer in digital medical device solutions for chronic pain, is proud to announce to been selected as one of seven prestigious participants in the inaugural 10XHEALTH program, a collaborative initiative by SmiLe Incubator and Medicon Village. The program is set to be launched in January 2024, with the aim of propelling established life science companies in Southern Sweden toward accelerated international growth.

Läs mer
Read more
No items found.
12/21/2023

Paindrainer AB enters the U.S. market by successfully securing its first commercial partnership

Paindrainer AB is pleased to announce the formalization of a commercial partnership agreement with Dr. Edward Rubin, Past President of The New York Society of Interventional Pain Physicians. This strategic collaboration accomplishes a crucial milestone, allowing Paindrainer AB access to the U.S. market with its groundbreaking FDA registered Medical Device Class I digital solution for chronic pain management.

Läs mer
Read more
No items found.
10/19/2023

Paindrainer AB and IHE publish US Health Economic Study highlighting excessive cost to society and payers for chronic pain

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, in collaboration with the Institute of Health Economics (IHE), has undertaken and unveiled considerable costs in a health economic study. The study underscores the substantial impact of chronic pain on the cost to both society, health organisations and payers. In addition, it also sheds light on the potential for improvement through the utilization of a digital self-management tool like Paindrainer®.

Read more
No items found.
9/26/2023

Paindrainer AB and the Swedish Association of Fibromyalgia has signed an agreement offering their members the novel digital coach for improved quality of life

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB is pleased to announce that the company has signed a commercial agreement with the Swedish Fibromyalgia Association, offering Paindrainer® as a complimentary membership benefit.

Read more
No items found.
9/1/2023

Paindrainer® secures certification by ORCHA – the world’s leading digital health evaluation organization

LUND, SWEDEN – The company is pleased to announce that the Paindrainer® App has been certified by the Organization for the Review of Care and Health Apps (ORCHA). ORCHA is the world’s leading, independent digital health evaluation and distribution organization, providing verification and certification, which is trusted and accepted by health-care organizations internationally.

Read more
No items found.
8/15/2023

Paindrainer® wins the prestigious Nordic Health App Award 2023

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB is proud to announce that the company’s 360° patient-centric© app Paindrainer® was announced as the winner of the Nordic Health App Award 2023 at the “Arendalsuka” in Norway.

Läs mer
Read more
No items found.
8/10/2023

Paindrainer AB´s digital tool is the first device targeting chronic pain to receive FDA registration approval as a Medical Device Class 1

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB is pleased to announce that the company’s 360° patient-centric© app (Paindrainer® PD1) has received registration approval as a Medical Device Class 1 (510k exemption) by the U.S. Food and Drug Administration (FDA).

Read more